The biology of brain metastases-translation to new therapies

Nature Reviews Clinical Oncology

Volumn 8, Issue 6, 2011, Pages 344-356

  Eichler, April F ^a   Chung, Euiheon ^b   Kodack, David P ^b   Loeffler, Jay S ^b   Fukumura, Dai ^b   Jain, Rakesh K ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANGIOGENIC FACTOR; B RAF KINASE INHIBITOR; CAPECITABINE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GRN 1005; GSK 2118436; LAPATINIB; PACLITAXEL; PACLITAXEL DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VEMURAFENIB; VORINOSTAT;

ANTIANGIOGENIC THERAPY; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN METASTASIS; BRAIN MICROENVIRONMENT; BRAIN RADIATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MODEL; DRUG MECHANISM; GLIOMA; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MICROENVIRONMENT; MOLECULARLY TARGETED THERAPY; NEUROIMAGING; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SPONTANEOUS METASTASIS; STROMA CELL; TUMOR CELL; TUMOR VASCULARIZATION; WHOLE BRAIN RADIATION THERAPY;

ANIMALS; BLOOD-BRAIN BARRIER; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; NEOPLASMS;

EID: 79958045766     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.58     Document Type: Review

References (161)

1. Gavrilovic, I. T. & Posner, J. B. Brain metastases: epidemiology and pathophysiology. J. Neurooncol. 75, 5-14 (2005). (Pubitemid 41548673)
2. Barnholtz-Sloan, J. S. et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22, 2865-2872 (2004). (Pubitemid 41079905)
3. Schouten, L. J., Rutten, J., Huveneers, H. A. & Twijnstra, A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94, 2698-2705 (2002). (Pubitemid 34478086)
4. Delattre, J. Y., Krol, G., Thaler, H. T. & Posner, J. B. Distribution of brain metastases. Arch. Neurol. 45, 741-744 (1988).
5. Chang, E. L. et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 60, 277-283 (2007).
6. Mehta, M. P. et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 21, 2529-2536 (2003). (Pubitemid 46606335)
7. Gaspar, L. et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37, 745-751 (1997). (Pubitemid 27181303)
8. Melisko, M. E., Moore, D. H., Sneed, P. K., De Franco, J. & Rugo, H. S. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J. Neurooncol. 88, 359-365 (2008).
9. Eichler, A. F. et al. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112, 2359-2367 (2008).
10. Eichler, A. F. et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 12, 1193-1199 (2010).
11. Patchell, R. A. et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494-500 (1990). (Pubitemid 20067825)
12. Vecht, C. J. et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann. Neurol. 33, 583-590 (1993). (Pubitemid 23161878)
13. Andrews, D. W. et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665-1672 (2004). (Pubitemid 38670323)
14. Aoyama, H. et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483-2491 (2006). (Pubitemid 43854963)
15. Kocher, M. et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J. Clin. Oncol. 29, 134-141 (2011).
16. Antonadou, D. et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. 20, 3644-3650 (2002). (Pubitemid 34983224)
17. Robinet, G. et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann. Oncol. 12, 59-67 (2001). (Pubitemid 32162449)
18. Verger, E. et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 61, 185-191 (2005). (Pubitemid 40039121)
19. Talmadge, J. E. & Fidler, I. J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 70, 5649-5669 (2010).
20. Hess, K. R. et al. Metastatic patterns in adenocarcinoma. Cancer 106, 1624-33 (2006).
21. Patel, J. K., Didolkar, M. S., Pickren, J. W. & Moore, R. H. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am. J. Surg. 135, 807-10 (1978). (Pubitemid 8377329)
22. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 133, 571-573 (1889).
23. Ewing, J. Neoplastic Diseases. A Treatise on Tumors (W. B. Saunders Co., Philadelphia and London, 1928).
24. Duda, D. G. et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl Acad. Sci. USA 107, 21677-21682 (2010).
25. Kienast, Y. et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16, 116-122 (2010).
26. Lorger, M. & Felding-Habermann, B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am. J. Pathol. 176, 2958-2971 (2010).
27. Carbonell, W. S., Ansorge, O., Sibson, N. & Muschel, R. The vascular basement membrane as "soil" in brain metastasis. PLoS ONE 4, e5857 (2009).
28. Fitzgerald, D. P. et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin. Exp. Metastasis 25, 799-810 (2008).
29. Zhang, M. & Olsson, Y. Reactions of astrocytes and microglial cells around hematogenous metastases of the human brain. Expression of endothelin-like immunoreactivity in reactive astrocytes and activation of microglial cells. J. Neurol. Sci. 134, 26-32 (1995).
30. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252 (2009).
31. Pukrop, T. et al. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 58, 1477-1489 (2010).
32. He, B. P. et al. Differential reactions of microglia to brain metastasis of lung cancer. Mol. Med. 12, 161-170 (2006). (Pubitemid 44646345)
33. Fidler, I. J. The role of the organ microenvironment in brain metastasis. Semin. Cancer Biol. 21, 107-112 (2011).
34. Langley, R. R. et al. Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis. Int. J. Oncol. 35, 665-672 (2009).
35. Lin, Q. et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12, 748-754 (2010).
36. Kim, S. J. et al. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy Neoplasia 13, 286-298 (2011).
37. Seike, T. et al. Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis. Clin. Exp. Metastasis 28, 13-25 (2010).
38. Denkins, Y. et al. Brain metastases in melanoma: roles of neurotrophins. Neuro Oncol. 6, 154-165 (2004). (Pubitemid 38455762)
39. Menter, D. G., Herrmann, J. L. & Nicolson, G. L. The role of trophic factors and autocrine/paracrine growth factors in brain metastasis. Clin. Exp. Metastasis 13, 67-88 (1995).
40. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
41. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286 (2007). (Pubitemid 46505878)
42. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature (in press).
43. Jain, R. K. et al. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610-622 (2007). (Pubitemid 47093931)
44. Ricci-Vitiani, L. et al. Tumour vascularization via endothelial differentiation of glioblastoma stemlike cells. Nature 468, 824-828 (2010).
45. Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829-833 (2010).
46. Di Tomaso, E. et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 71, 19-28 (2011).
47. Soda, Y. et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl Acad. Sci. USA 108, 4274-4280 (2011).
48. 165 induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 62, 341-345 (2002). (Pubitemid 34106399)
49. Leenders, W. P. et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin. Cancer Res. 10, 6222-6230 (2004). (Pubitemid 39287530)
50. Fidler, I. J., Yano, S., Zhang, R. D., Fujimaki, T. & Bucana, C. D. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 3, 53-57 (2002). (Pubitemid 34121146)
51. Yano, S. et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 60, 4959-4967 (2000).
52. Kim, L. S., Huang, S., Lu, W., Lev, D. C. & Price, J. E. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis 21, 107-118 (2004). (Pubitemid 38988084)
53. JuanYin, J. et al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin. Exp. Metastasis 26, 403-414 (2009).
54. 3 controls angiogenesis and metastatic growth in the brain. Proc. Natl Acad. Sci. USA 106, 10666-10671 (2009).
55. Hiratsuka, S. et al. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc. Natl Acad. Sci. USA 108, 302-307 (2011).
56. Bullitt, E. et al. Vessel tortuosity and brain tumor malignancy: a blinded study. Acad. Radiol. 12, 1232-1240 (2005). (Pubitemid 41354249)
57. Feigin, I., Allen, L. B., Lipkin, L. & Gross, S. W. The endothelial hyperplasia of the cerebral blood vessels with brain tumors, and its sarcomatous transformation. Cancer 11, 264-277 (1958).
58. Yuan, F. et al. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 54, 4564-4568 (1994). (Pubitemid 24276471)
59. Hiratsuka, S. et al. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin upregulation. Proc. Natl Acad. Sci. USA 108, 3725-3730 (2011).
60. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
61. Fukumura, D., Duda, D. G., Munn, L. L. & Jain, R. K. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17, 206-225 (2010).
62. Cranmer, L. D., Trevor, K. T, Bandlamuri, S. & Hersh, E. M. Rodent models of brain metastasis in melanoma. Melanoma Res. 15, 325-356 (2005). (Pubitemid 41558944)
63. Cruz-Munoz, W., Man, S., Xu, P & Kerbel, R. S. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res. 68, 4500-4505 (2008).
64. Mathieu, A. et al. Development of a chemoresistant orthotopic human nonsmall cel lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-α, GST-μ, and GST-it. Cancer 101, 1908-1918 (2004). (Pubitemid 39328201)
65. Chen, E. I. et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 67, 1472-1486 (2007). (Pubitemid 46383371)
66. Monsky, W. L. et al. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin. Cancer Res. 8, 1008-1013 (2002). (Pubitemid 35177349)
67. Price, J. E. Metastasis from human breast cancer cell lines. Breast Cancer Res. Treat. 39, 93-102 (1996). (Pubitemid 26136507)
68. Price, J. E., Polyzos, A., Zhang, R. D. & Daniels, L. M. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50, 717-721 (1990). (Pubitemid 20054204)
69. Rye, P D. et al. Brain metastasis model in athymic nude mice using a novel MUC1-secreting human breast-cancer cell line, MA11. Int J. Cancer 68, 682-687 (1996). (Pubitemid 26414532)
70. Yoneda, T, Williams, P J., Hiraga, T, Niewolna, M. & Nishimura, R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Miner. Res. 16, 1486-1495 (2001). (Pubitemid 32675200)
71. Zhang, R. D., Fidler, I. J. & Price, J. E. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 11, 204-215 (1991).
72. Fidler, I. J., Schackert, G., Zhang, R. D., Radinsky, R. & Fujimaki, T. The biology of melanoma brain metastasis. Cancer Metastasis Rev. 18, 387-400 (1999). (Pubitemid 30104071)
73. Palmieri, D. et al. HER-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 67, 4190-4198 (2007). (Pubitemid 46815065)
74. Gril, B. et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl Cancer Inst. 100, 1092-1103 (2008).
75. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280 (2002). (Pubitemid 34260234)
76. Chung, E. et al. Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 4, e8316 (2009).
77. Alterman, A. L. & Stackpole, C. W. B16 melanoma spontaneous brain metastasis: occurrence and development within leptomeninges blood vessels. Clin. Exp. Metastasis 7, 15-23 (1989). (Pubitemid 19021785)
78. Bos, P. D. et al. Genes that mediate breast cancer metastasis to the brain. Nature 459, 1005-1009 (2009).
79. Lockman, P. R. et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in mouse brain metastases of breast cancer. Clin. Cancer Res. 16, 5664-5678 (2010).
80. Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer 2, 11-18 (2002). (Pubitemid 37328803)
81. Weissleder, R. & Pittet, M. J. Imaging in the era of molecular oncology. Nature 452, 580-589 (2008). (Pubitemid 351483372)
82. Anderson, S. A. & Frank, J. A. MRI of mouse models of neurological disorders. NMR Biomed. 20, 200-215 (2007). (Pubitemid 46824527)
83. Frank, J. A. et al. Methods for magnetically labeling stem and other cells for detection by in vivo magnetic resonance imaging. Cytotherapy 6, 621-625 (2004). (Pubitemid 40028925)
84. Heyn, C. et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn. Reson. Med. 56, 1001-1010 (2006). (Pubitemid 44691342)
85. * imaging of metastatic human breast cancer to brain in the nude rat at 3 T. NMR Biomed. 24, 325-334 (2011).
86. Song, H. T. et al. Rat model of metastatic breast cancer monitored by MRI at 3 tesla and bioluminescence imaging with histological correlation. J. Transl. Med. 7, 88 (2009).
87. Abbott, N. J., Rönnbäck, L. & Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7, 41-53 (2006). (Pubitemid 41828930)
88. Neuwelt, E. A. Mechanisms of disease: the blood-brain barrier. Neurosurgery 54, 131-140 (2004).
89. Deeken, J. F. & Loscher, W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13, 1663-1674 (2007). (Pubitemid 46952931)
90. Fukumura, D. et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61, 6020-6024 (2001). (Pubitemid 32762531)
91. Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607-4612 (1998). (Pubitemid 28207960)
92. Monsky, W. L. et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59, 4129-4135 (1999). (Pubitemid 29393588)
93. Zhang, R. D., Price, J. E., Fujimaki, T., Bucana, C. D. & Fidler, I. J. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am. J. Pathol. 141, 1115-1124 (1992).
94. Regina, A. et al. Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev. 20, 13-25 (2001). (Pubitemid 34074674)
95. Patchell, R. A. et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280, 1485-1489 (1998). (Pubitemid 28507400)
96. de Boer, A. G. & Gaillard, P. J. Strategies to improve drug delivery across the blood-brain barrier. Clin. Pharmacokinet. 46, 553-576 (2007). (Pubitemid 47025357)
97. Lillis, A. P., Van Duyn, L. B., Murphy-Ullrich, J. E. & Strickland, D. K. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 88, 887-918 (2008).
98. Pardridge, W. M. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug. Chem. 19, 1327-1338 (2008). (Pubitemid 352032329)
99. Bu, G., Maksymovitch, E. A., Geuze, H. & Schwartz, A. L. Subcellular localization and endocytic function of low density lipoprotein receptor-related protein in human glioblastoma cells. J. Biol. Chem. 269, 29874-29882 (1994). (Pubitemid 24365153)
100. Demeule, M. et al. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. 83, 924-933 (2002). (Pubitemid 35316043)
101. Pan, W. et al. Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci. 117, 5071-5078 (2004). (Pubitemid 39517522)
102. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00539383 (2010).
103. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00539344 (2010).
104. Regina, A. et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155, 185-197 (2008).
105. Thomas, F. C. et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26, 2486-2494 (2009).
106. DeAngelis, L. M. et al. The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J. Neurooncol. 7, 241-247 (1989). (Pubitemid 19225514)
107. Eyre, H. J. et al. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J. Neurooncol. 2, 325-330 (1984). (Pubitemid 15191842)
108. Komarnicky, L. T. et al. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int. J. Radiat. Oncol. Biol. Phys. 20, 53-58 (1991).
109. Mehta, M. P. et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 73, 1069-1076 (2009).
110. Phillips, T. L., Scott, C. B., Leibel, S. A., Rotman, M. & Weigensberg, I. J. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05 Int. J. Radiat. Oncol. Biol. Phys. 33, 339-348 (1995).
111. Suh, J. H. et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J. Clin. Oncol. 24, 106-114 (2006). (Pubitemid 46630501)
112. Neuhaus, T. et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br. J. Cancer 100, 291-297 (2009).
113. Baschnagel, A. et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol. Cancer Ther. 8, 1589-1595 (2009).
114. Palmieri, D. et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA doublestrand breaks. Clin. Cancer Res. 15, 6148-6157 (2009).
115. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00838929 (2011).
116. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00946673 (2010).
117. Besse, B. et al. Bevacizumab safety in patients with central nervous system metastases. Clin. Cancer Res. 16, 269-278 (2010).
118. Socinski, M. A. et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 27, 5255-5261 (2009).
119. Polikoff, J. et al. Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS [abstract]. J. Clin. Oncol. 26 (15 Suppl.), a8079 (2008).
120. De Braganca, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J. Neurooncol. 100, 443-447 (2010).
121. Eichler, A. F. et al. A phase I study of cediranib plus whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer [abstract]. J. Clin. Oncol. 28 (15 Suppl.), TPS177 (2010).
122. Ceresoli, G. L. et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann. Oncol. 15, 1042-1047 (2004). (Pubitemid 39089780)
123. Wu, C. et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57, 359-364 (2007). (Pubitemid 47285416)
124. Fekrazad, M. H., Ravindranathan, M. & Jones, D. V. Jr. Response of intracranial metastases to erlotinib therapy. J. Clin. Oncol. 25, 5024-5026 (2007). (Pubitemid 350220437)
125. Lai, C. S., Boshoff, C., Falzon, M. & Lee, S. M. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 61, 91 (2006). (Pubitemid 43106986)
126. Popat, S. et al. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 56, 135-137 (2007). (Pubitemid 46356639)
127. Kim, J. E. et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65, 351-354 (2009).
128. Paz-Ares, L. et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 24, 1428-1434 (2006). (Pubitemid 46622009)
129. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
130. Leyland-Jones, B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J. Clin. Oncol. 27, 5278-5286 (2009).
131. Lin, N. U. & Winer, E. P. Brain metastases: the HER2 paradigm. Clin. Cancer Res. 13, 1648-1655 (2007). (Pubitemid 46952930)
132. Zhang, L., Sullivan, P. S., Goodman, J. C., Gunaratne, P. H. & Marchetti, D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 71, 645-654 (2011).
133. Lin, N. U. et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 26, 1993-1999 (2008).
134. Lin, N. U. et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15, 1452-1459 (2009).
135. Cameron, D. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112, 533-543 (2008).
136. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01004172 (2011).
137. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
138. Long, G. V. et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (MUT) BRAF kinase; evidence of activity in melanoma brain metastases (METS) [abstract]. Ann. Oncol. 21, viii12 (2010).
139. Felding-Habermann, B. et al. Integrin activation controls metastasis in human breast cancer. Proc. Natl Acad. Sci. USA 98, 1853-1858 (2001). (Pubitemid 32165587)
140. Palmieri, D. et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol. Cancer Res. 7, 1438-1445 (2009).
141. Ray, P. S. et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 70, 3870-3876 (2010).
142. Nguyen, D. X. et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138, 51-62 (2009).
143. Grinberg-Rashi, H. et al. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin. Cancer Res. 15, 1755-1761 (2009).
144. Xie, T. X. et al. Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res. 66, 3188-3196 (2006).
145. Nam, D. H. et al. Activation of notch signaling in a xenograft model of brain metastasis. Clin. Cancer Res. 14, 4059-4066 (2008).
146. Siegal, T. et al. Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study. J. Neurooncol. 4, 233-242 (1987). (Pubitemid 17023824)
147. Schabet, M. & Herrlinger, U. Animal models of leptomeningeal metastasis. J. Neurooncol. 38, 199-205 (1998). (Pubitemid 28306208)
148. Schackert, G., Price, J. E., Bucana, C. D. & Fidler, I. J. Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. Int. J. Cancer 44, 892-897 (1989). (Pubitemid 20007989)
149. Broder, H., Anderson, A., Kremen, T. J., Odesa, S. K. & Liau, L. M. MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor. J. Neurooncol. 64, 21-30 (2003). (Pubitemid 36992457)
150. Schackert, G. & Fidler, I. J. Development of in vivo models for studies of brain metastasis. Int. J. Cancer 41, 589-594 (1988).
151. Schackert, G. & Fidler, I. J. Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals. Cancer Res. 48, 3478-3484 (1988).
152. Yang, M. et al. Genetically fluorescent melanoma bone and organ metastasis models. Clin. Cancer Res. 5, 3549-3559 (1999).
153. Muldoon, L. L. et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25, 2295-2305 (2007). (Pubitemid 46954658)
154. Bellavance, M. A., Blanchette, M. & Fortin, D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J. 10, 166-177 (2008).
155. Gregor, A. et al. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group. J. Neurooncol. 44, 137-145 (1999).
156. Matsukado, K. et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39, 125-133 (1996).
157. Prados, M. D. et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol. 5, 96-103 (2003). (Pubitemid 36416838)
158. Jones, A. R. & Shusta, E. V. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24, 1759-1771 (2007). (Pubitemid 47206625)
159. Joo, K. M. et al. Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and p-glycoprotein inhibitor. Oncol. Rep. 19, 17-23 (2008). (Pubitemid 351176126)
160. Joo, K. M. et al. Response of brain specific microenvironment to p-glycoprotein inhibitor: an important factor determining therapeutic effect of p-glycoprotein inhibitor on brain metastatic tumors. Int. J. Oncol. 33, 705-712 (2008).
161. Bauer, B., Hartz, A. M., Fricker, G. & Miller, D. S. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp. Biol. Med. 230, 118-127 (2005).